Skin Grafts Market Size is estimated to grow at a significant rate from 2022 to 2028 on account of technological advancements in surgical procedures. Investment in research and development activities and innovations in dermatomes will foster industry growth.
Rising cases of burn injuries and skin infections have fueled the demand for skin graft surgery across North America and Europe. Skin grafts can enhance the appearance of damaged skin, replace lost skin and restore function. Surgery has become popular as an effective treatment for skin loss that results from various conditions. Skin grafting has become sought-after with the growing prominence of split-thickness skin grafts and full-thickness skin grafts.
With respect to graft thickness, split-thickness skin grafts will account for a considerable share owing to skin loss due to infection and reconstructive surgeries. Healthcare organizations have exhibited increased traction for split-thickness to cover large areas of missing or damaged skin. The graft will continue to play an instrumental role in the reconstructive ladder over the next few years.
Based on application, skin grafts market share from skin cancer will grow over 2022-2028 on account of rising cases of the disease globally. According to the American Academy of Dermatology Association, around 9,500 people are diagnosed with skin cancer in the U.S. every day. Besides, over 1 million Americans are living with melanoma. Industry players are likely to boost advancements amidst soaring demand for skin cancer surgery.
In terms of region, North America skin grafts market share will gain traction following the rise in extensive wounds, burns and skin cancer in the U.S. and Canada. A notable surge in the number of dermatology clinics, hospitals and ambulatory surgical centers will augur well for the regional expansion. Besides, the adoption of novel technology and rising purchasing power will encourage leading players to expand their footprint.
The competitiveness of global skin grafts market will be propelled by the presence of leading companies, such as Zimmer Biomet, B. Braun Melsungen AG, Avita Medical, Integra Lifesciences Corporation, Surtex Instruments Limited, Nouvag AG, MiMedx, Organogenesis, Inc., De Soutter Medical Limited and Tissue Regenix, among others. These companies are expected to invest in organic and inorganic strategies, including mergers & acquisitions, R&D activities, innovation and product launches.
In August 2021, Avita Medical announced that the U.S. FDA approved its request to amend the clinical trial assessing the effectiveness and safety of the RECELL System for vitiligo treatment. In the wake of the successful completion of the clinical trial, the company expects to foray into the U.S. market with the vitiligo indication in 2023.
The onslaught of coronavirus led to limited availability of fully processed skin for use on burn patients across emerging economies, such as India and Brazil. Moreover, the shortage of skilled healthcare workers did not bode well for the industry outlook. A plunge in non-urgent medical visits or delayed diagnosis of melanoma and other skin cancers hampered the business expansion. That said, the post-COVID outlook indicates investment in healthcare budgets and rollout of vaccination and boosters could foster skin grafts industry forecast.
Given the impact of the COVID-19 outbreak, investments across hospital outpatient and ambulatory surgical settings are expected to rise. Moreover, technological improvements in the treatment of burns will boost the penetration of skin graft solutions globally.
Market, by types
Market, by graft thickness
Market, by application
Market, by end-use
The above information is provided for the following regions and countries: